Anti-Recombinant-HHV-8 antibody [LN53] (STJ180610)

SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
IsotypeIgG2ck
ImmunogenProtein corresponding to the latent nuclear antigen 1 molecule of HHV-8
STJ180610
🚚 Free UK Delivery on orders over £150
Processing The item has been added
Enquire For Bulk Order
✓ 1-Year Performance Guarantee | SDS & Datasheet Included | Expert Tech Support | Covered by St John's Laboratory Guarantee

General Information

Short DescriptionMouse monoclonal Recombinant-HHV-8 antibody for use in IHC-P in human samples. Datasheet included with dilution recommendations, and related reagents.
ApplicationsIHC-P
HostMouse
ReactivityHuman
NoteSTRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.

Product Properties

ClonalityMonoclonal
Clone IDLN53
IsotypeIgG2ck
ConjugationUnconjugated
PurificationAffinity purified
Dilution Range1:100-200
FormulationTris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin
Storage InstructionStore at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C.

Target Information

ImmunogenProtein corresponding to the latent nuclear antigen 1 molecule of HHV-8
SpecificityPositive Control: Kaposi's sarcoma

Additional Info

Background Zeta HHV8 Antibody. Zeta s recombinant mouse antibody recognizes HHV8, which encodes a latent nuclear antigen (LNA) , which is the product of the viral gene orf 73. LNA is capable of forming a complex with retinoblastoma susceptibility gene product, which may be related to its oncogenic activity. HHV8 is associated with three different diseases observed in AIDS patients: Kaposi s sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman s disease. HHV8 is the likely etiological agent of Kaposi s sarcoma. Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.

Information sourced from Uniprot.org

Citations

Product Review

Well-cited Academic Publications
KO-Validated 700+ Lines
Technical Support Expert Scientific Team
1-Year Guarantee Antibodies & Proteins